SG Americas Securities LLC Increases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

VaselineAugust 22, 2024

0 4 minutes read

SG Americas Securities LLC grew its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 255.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,858 shares of the company’s stock after buying an additional 9,242 shares during the period. SG Americas Securities LLC’s holdings in Pacira BioSciences were worth $368,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. QRG Capital Management Inc. grew its stake in shares of Pacira BioSciences by 37.9% during the 2nd quarter. QRG Capital Management Inc. now owns 31,309 shares of the company’s stock valued at $896,000 after buying an additional 8,601 shares during the period. GAMMA Investing LLC boosted its position in Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp purchased a new stake in Pacira BioSciences during the 2nd quarter worth $46,000. Jane Street Group LLC boosted its position in Pacira BioSciences by 1,780.2% during the 1st quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock worth $5,480,000 after purchasing an additional 177,557 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in Pacira BioSciences during the 1st quarter worth $209,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PCRX. StockNews.com cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Royal Bank of Canada cut shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $37.00 to $14.00 in a research report on Monday, August 12th. Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, Piper Sandler cut shares of Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $42.00 to $11.00 in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.78.

Want More Great Investing Ideas?

View Our Latest Stock Report on PCRX

Insider Activity

In related news, SVP Lauren Riker sold 3,970 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the sale, the senior vice president now owns 38,075 shares in the company, valued at $1,093,514. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Lauren Riker sold 3,970 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the sale, the senior vice president now owns 38,075 shares in the company, valued at $1,093,514. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kristen Williams sold 7,452 shares of the stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $28.38, for a total transaction of $211,487.76. Following the sale, the insider now owns 102,912 shares in the company, valued at approximately $2,920,642.56. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 11,176 shares of company stock worth $136,240 and have sold 22,095 shares worth $621,118. Company insiders own 6.40% of the company’s stock.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $13.85 on Thursday. The firm has a market cap of $644.66 million, a PE ratio of 9.69 and a beta of 0.88. The firm’s 50-day simple moving average is $21.38 and its 200-day simple moving average is $26.33. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $38.23.

Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last issued its earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.11. The business had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. Equities analysts forecast that Pacira BioSciences, Inc. will post 2.22 earnings per share for the current fiscal year.

Pacira BioSciences Profile

(Free Report)

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.